On November 15, 2024, the Unified Patent Court's Local Division in Munich ruled in favor of Edwards Lifesciences in a patent infringement case against Meril GmbH and Meril Life Sciences Pvt Ltd. The court found that Meril's 'Myval Octacor' valve and associated delivery systems infringed on Edwards' European Patent EP 3 646 825, which covers prosthetic heart valve technology.
The court ordered an injunction and other corrective measures against Meril, upholding Edwards' patent in an amended form. This decision protects Edwards' intellectual property and its market position in the competitive heart valve technology sector.
The ruling also addressed third-party and public interest concerns by confirming that Edwards' Medical Request Portal adequately provides access to XL-sized valve prostheses when clinically necessary. This mechanism allows for patient needs to be met while upholding patent rights and ensuring product safety.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.